228 related articles for article (PubMed ID: 15562379)
1. Circulating osteoprotegerin levels are associated with age, waist-to-hip ratio, serum total cholesterol, and low-density lipoprotein cholesterol levels in healthy Korean women.
Oh ES; Rhee EJ; Oh KW; Lee WY; Baek KH; Yoon KH; Kang MI; Yun EJ; Park CY; Choi MG; Yoo HJ; Park SW
Metabolism; 2005 Jan; 54(1):49-54. PubMed ID: 15562379
[TBL] [Abstract][Full Text] [Related]
2. Serum levels of osteoprotegerin and receptor activator of nuclear factor-kappaB ligand as markers of periprosthetic osteolysis.
Granchi D; Pellacani A; Spina M; Cenni E; Savarino LM; Baldini N; Giunti A
J Bone Joint Surg Am; 2006 Jul; 88(7):1501-9. PubMed ID: 16818976
[TBL] [Abstract][Full Text] [Related]
3. [The relationships between changes of serum osteoprotegerin, nuclear factor-kappa B ligand receptor activator, and age, menopause, bone biochemical markers and bone mineral densities in women aged 20 - 75].
Liu JM; Zhao HY; Ning G; Zhao YJ; Chen Y; Zhang LZ; Xu MY; Chen JL
Zhonghua Nei Ke Za Zhi; 2004 Jun; 43(6):447-50. PubMed ID: 15312444
[TBL] [Abstract][Full Text] [Related]
4. Circulating amounts of osteoprotegerin and RANK ligand: genetic influence and relationship with BMD assessed in female twins.
Abrahamsen B; Hjelmborg JV; Kostenuik P; Stilgren LS; Kyvik K; Adamu S; Brixen K; Langdahl BL
Bone; 2005 Apr; 36(4):727-35. PubMed ID: 15781001
[TBL] [Abstract][Full Text] [Related]
5. Circulating estradiol and osteoprotegerin as determinants of bone turnover and bone density in postmenopausal women.
Rogers A; Saleh G; Hannon RA; Greenfield D; Eastell R
J Clin Endocrinol Metab; 2002 Oct; 87(10):4470-5. PubMed ID: 12364420
[TBL] [Abstract][Full Text] [Related]
6. Effects of oral contraceptives on circulating osteoprotegerin and soluble RANK ligand serum levels in healthy young women.
Hofbauer LC; Schoppet M; Schüller P; Viereck V; Christ M
Clin Endocrinol (Oxf); 2004 Feb; 60(2):214-9. PubMed ID: 14725683
[TBL] [Abstract][Full Text] [Related]
7. Relationships between the changes of serum levels of OPG and RANKL with age, menopause, bone biochemical markers and bone mineral density in Chinese women aged 20-75.
Liu JM; Zhao HY; Ning G; Zhao YJ; Chen Y; Zhang Zh; Sun LH; Xu MY; Chen JL
Calcif Tissue Int; 2005 Jan; 76(1):1-6. PubMed ID: 15455183
[TBL] [Abstract][Full Text] [Related]
8. The contribution of serum osteoprotegerin to bone mass and vertebral fractures in postmenopausal women.
Mezquita-Raya P; de la Higuera M; García DF; Alonso G; Ruiz-Requena ME; de Dios Luna J; Escobar-Jiménez F; Muñoz-Torres M
Osteoporos Int; 2005 Nov; 16(11):1368-74. PubMed ID: 15711777
[TBL] [Abstract][Full Text] [Related]
9. Serum osteoprotegerin and RANKL levels in chronic alcoholic liver disease.
García-Valdecasas-Campelo E; González-Reimers E; Santolaria-Fernández F; De la Vega-Prieto MJ; Milena-Abril A; Sánchez-Pérez MJ; Martínez-Riera A; Gómez-Rodríguez Mde L
Alcohol Alcohol; 2006; 41(3):261-6. PubMed ID: 16476762
[TBL] [Abstract][Full Text] [Related]
10. Serum osteoprotegerin and receptor activator of nuclear factors kB (RANKL) concentrations in normal children and in children with pubertal precocity, Turner's syndrome and rheumatoid arthritis.
Buzi F; Maccarinelli G; Guaragni B; Ruggeri F; Radetti G; Meini A; Mazzolari E; Cocchi D
Clin Endocrinol (Oxf); 2004 Jan; 60(1):87-91. PubMed ID: 14678293
[TBL] [Abstract][Full Text] [Related]
11. Circulating osteoprotegerin is correlated with lipid profile, insulin sensitivity, adiponectin and sex steroids in an ageing male population.
Gannagé-Yared MH; Fares F; Semaan M; Khalife S; Jambart S
Clin Endocrinol (Oxf); 2006 Jun; 64(6):652-8. PubMed ID: 16712667
[TBL] [Abstract][Full Text] [Related]
12. Serum osteoprotegerin is increased in Crohn's disease: a population-based case control study.
Bernstein CN; Sargent M; Leslie WD
Inflamm Bowel Dis; 2005 Apr; 11(4):325-30. PubMed ID: 15803021
[TBL] [Abstract][Full Text] [Related]
13. Correlation of osteoprotegerin and sRANKL concentrations in serum and bone marrow of multiple myeloma patients.
Kraj M; Owczarska K; Sokołowska U; Centkowski P; Pogłód R; Kruk B
Arch Immunol Ther Exp (Warsz); 2005; 53(5):454-64. PubMed ID: 16314829
[TBL] [Abstract][Full Text] [Related]
14. Osteoprotegerin (OPG) and receptor activator of NF-kB ligand (RANK-L) serum levels in patients on chronic hemodialysis.
Gonnelli S; Montagnani A; Caffarelli C; Cadirni A; Campagna MS; Franci MB; Lucani B; Gaggiotti E; Nuti R
J Endocrinol Invest; 2005 Jun; 28(6):534-9. PubMed ID: 16117195
[TBL] [Abstract][Full Text] [Related]
15. The relationship between four single nucleotide polymorphisms in the promoter region of the osteoprotegerin gene and aortic calcification or coronary artery disease in Koreans.
Rhee EJ; Oh KW; Jung CH; Lee WY; Oh ES; Yun EJ; Baek KH; Kang MI; Kim SW
Clin Endocrinol (Oxf); 2006 Jun; 64(6):689-97. PubMed ID: 16712673
[TBL] [Abstract][Full Text] [Related]
16. Soluble receptor activator of nuclear factor- kappaB Ligand (sRANKL)/osteoprotegerin balance in ageing and age-associated diseases.
Pulsatelli L; Dolzani P; Silvestri T; Caraceni P; Facchini A; Ravaglia G; Salvarani C; Melicòni R; Mariani E
Biogerontology; 2004; 5(2):119-27. PubMed ID: 15105586
[TBL] [Abstract][Full Text] [Related]
17. Serum osteoprotegerin and its ligand in Paget's disease of bone: relationship to disease activity and effect of treatment with bisphosphonates.
Alvarez L; Peris P; Guañabens N; Vidal S; Ros I; Pons F; Filella X; Monegal A; Muñoz-Gomez J; Ballesta AM
Arthritis Rheum; 2003 Mar; 48(3):824-8. PubMed ID: 12632438
[TBL] [Abstract][Full Text] [Related]
18. The relationship between circulating osteoprotegerin levels and bone mineral metabolism in healthy women.
Oh KW; Rhee EJ; Lee WY; Kim SW; Oh ES; Baek KH; Kang MI; Choi MG; Yoo HJ; Park SW
Clin Endocrinol (Oxf); 2004 Aug; 61(2):244-9. PubMed ID: 15272921
[TBL] [Abstract][Full Text] [Related]
19. Osteoprotegerin and RANKL in alcoholic liver cirrhosis.
Fábrega E; Orive A; García-Suarez C; García-Unzueta M; Antonio Amado J; Pons-Romero F
Liver Int; 2005 Apr; 25(2):305-10. PubMed ID: 15780054
[TBL] [Abstract][Full Text] [Related]
20. Osteoprotegerin (OPG)/RANK-L system in juvenile idiopathic arthritis: is there a potential modulating role for OPG/RANK-L in bone injury?
Masi L; Simonini G; Piscitelli E; Del Monte F; Giani T; Cimaz R; Vierucci S; Brandi ML; Falcini F
J Rheumatol; 2004 May; 31(5):986-91. PubMed ID: 15124262
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]